Literature DB >> 33447664

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study.

Robert W Aldridge1, Dan Lewer1,2, Sarah Beale1,2, Anne M Johnson3, Maria Zambon4, Andrew C Hayward2, Ellen B Fragaszy1,5.   

Abstract

Background: There is currently a pandemic caused by the novel coronavirus SARS-CoV-2. The intensity and duration of this first and second waves in the UK may be dependent on whether SARS-CoV-2 transmits more effectively in the winter than the summer and the UK Government response is partially built upon the assumption that those infected will develop immunity to reinfection in the short term. In this paper we examine evidence for seasonality and immunity to laboratory-confirmed seasonal coronavirus (HCoV) from a prospective cohort study in England.
Methods: In this analysis of the Flu Watch cohort, we examine seasonal trends for PCR-confirmed coronavirus infections (HCoV-NL63, HCoV-OC43, and HCoV-229E) in all participants during winter seasons (2006-2007, 2007-2008, 2008-2009) and during the first wave of the 2009 H1N1 influenza pandemic (May-Sep 2009). We also included data from the pandemic and 'post-pandemic' winter seasons (2009-2010 and 2010-2011) to identify individuals with two confirmed HCoV infections and examine evidence for immunity against homologous reinfection.
Results: We tested 1,104 swabs taken during respiratory illness and detected HCoV in 199 during the first four seasons. The rate of confirmed HCoV infection across all seasons was 390 (95% CI 338-448) per 100,000 person-weeks; highest in the Nov-Mar 2008/9 season at 674 (95%CI 537-835) per 100,000 person-weeks. The highest rate was in February at 759 (95% CI 580-975) per 100,000 person-weeks. Data collected during May-Sep 2009 showed there was small amounts of ongoing transmission, with four cases detected during this period. Eight participants had two confirmed infections, of which none had the same strain twice.
Conclusion: Our results provide evidence that HCoV infection in England is most intense in winter, but that there is a small amount of ongoing transmission during summer periods. We found some evidence of immunity against homologous reinfection. Copyright:
© 2020 Aldridge RW et al.

Entities:  

Keywords:  HCoV-229E; HCoV-NL63; HCoV-OC43; SARS-CoV-2; epidemiology; pandemic; public health

Year:  2020        PMID: 33447664      PMCID: PMC7786426.2          DOI: 10.12688/wellcomeopenres.15812.2

Source DB:  PubMed          Journal:  Wellcome Open Res        ISSN: 2398-502X


  20 in total

1.  Is a healthy microbiome responsible for lower mortality in COVID-19?

Authors:  Lubomír Janda; Matúš Mihalčin; Michaela Šťastná
Journal:  Biologia (Bratisl)       Date:  2020-10-15       Impact factor: 1.350

2.  Household transmission of seasonal coronavirus infections: Results from the Flu Watch cohort study.

Authors:  Sarah Beale; Dan Lewer; Robert W Aldridge; Anne M Johnson; Maria Zambon; Andrew Hayward; Ellen Fragaszy
Journal:  Wellcome Open Res       Date:  2020-06-19

3.  Validation of a commercially available indirect assay for SARS-CoV-2 neutralising antibodies using a pseudotyped virus assay.

Authors:  Matthew J Murray; Megan McIntosh; Claire Atkinson; Tabitha Mahungu; Edward Wright; Wendy Chatterton; Michael Gandy; Matthew B Reeves
Journal:  J Infect       Date:  2021-03-20       Impact factor: 6.072

4.  A human coronavirus evolves antigenically to escape antibody immunity.

Authors:  Rachel T Eguia; Katharine H D Crawford; Terry Stevens-Ayers; Laurel Kelnhofer-Millevolte; Alexander L Greninger; Janet A Englund; Michael J Boeckh; Jesse D Bloom
Journal:  PLoS Pathog       Date:  2021-04-08       Impact factor: 6.823

Review 5.  Origin, Pathogenesis, Diagnosis and Treatment Options for SARS-CoV-2: A Review.

Authors:  Humna Sajjad; Mohsin Majeed; Saiqa Imtiaz; Mariyam Siddiqah; Anila Sajjad; Misbahud Din; Muhammad Ali
Journal:  Biologia (Bratisl)       Date:  2021-06-02       Impact factor: 1.653

6.  Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients.

Authors:  Moritz Anft; Arturo Blazquez-Navarro; Ulrik Stervbo; Sarah Skrzypczyk; Oliver Witzke; Rainer Wirth; Mira Choi; Christian Hugo; Petra Reinke; Toni Luise Meister; Eike Steinmann; Stephanie Pfaender; Peter Schenker; Richard Viebahn; Timm H Westhoff; Nina Babel
Journal:  J Nephrol       Date:  2021-07-06       Impact factor: 3.902

7.  Hand Hygiene Practices and the Risk of Human Coronavirus Infections in a UK Community Cohort.

Authors:  Sarah Beale; Anne M Johnson; Maria Zambon; Andrew C Hayward; Ellen B Fragaszy
Journal:  Wellcome Open Res       Date:  2021-06-22

8.  Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study.

Authors:  Dvir Aran; Daniel C Beachler; Stephan Lanes; J Marc Overhage
Journal:  J Infect       Date:  2020-10-27       Impact factor: 6.072

9.  Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.

Authors:  Kevin W Ng; Nikhil Faulkner; Georgina H Cornish; Annachiara Rosa; Ruth Harvey; Saira Hussain; Rachel Ulferts; Christopher Earl; Antoni G Wrobel; Donald J Benton; Chloe Roustan; William Bolland; Rachael Thompson; Ana Agua-Doce; Philip Hobson; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine F Houlihan; Kirsty Thomson; Emilie Sanchez; Gee Yen Shin; Moira J Spyer; Dhira Joshi; Nicola O'Reilly; Philip A Walker; Svend Kjaer; Andrew Riddell; Catherine Moore; Bethany R Jebson; Meredyth Wilkinson; Lucy R Marshall; Elizabeth C Rosser; Anna Radziszewska; Hannah Peckham; Coziana Ciurtin; Lucy R Wedderburn; Rupert Beale; Charles Swanton; Sonia Gandhi; Brigitta Stockinger; John McCauley; Steve J Gamblin; Laura E McCoy; Peter Cherepanov; Eleni Nastouli; George Kassiotis
Journal:  Science       Date:  2020-11-06       Impact factor: 47.728

Review 10.  Antibody and B cell responses to SARS-CoV-2 infection and vaccination.

Authors:  Katharina Röltgen; Scott D Boyd
Journal:  Cell Host Microbe       Date:  2021-06-17       Impact factor: 21.023

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.